Skip to main content
DFTX logo

DFTX · Definium Therapeutics, Inc.

Track DFTX — free
$29.12 -0.26 (-0.88%) At close · Nov 18
Market Cap
$3.99B
Shares
136.90M
Volume · Nov 18 1.92M Avg daily vol (3M) 1.96M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$29.12 Open$29.36 Day$28.24–29.85 52W close$10.68–48.45 Avg vol 30d1.7M Short int9.6M · 7.0% of shares · 5.8d Short vol68% Last earningsNov 9, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 9

Up next

Jan 6, 2027 Est · unconfirmed · in 7 wks

Latest documents

2026
Nov 17
Investor event
DT120 NDA filing expected in first half of next year after three positive pivotal trials

Definium's CEO said the company expects to file an NDA for DT120 in the first half of next year after three positive pivotal readouts in generalized anxiety disorder and major depressive disorder. A second major depressive disorder pivotal readout is expected in 2027.

4 source passages
And over the summer, we had three positive pivotal readouts in generalized anxiety disorder and major depressive disorder. We will have, we expect it to be filing our NDA in the first half of next year, and we're getting ready to We'll have, in 2027, a readout from our fourth pivotal study, our second study in major depressive disorder. If successful, we could get in a place where we're launching DT120 for both indications Open the document at this passage
Nov 10
Investor event
Three positive DT120 studies precede planned FDA NDA

Definium Therapeutics reported three positive phase three readouts for DT120—two in GAD and one in MDD—and plans to submit an NDA to FDA in the first half of next year for both indications.

3 source passages
Happy to be here with Dan Carlin, Chief Medical Officer of Definium Therapeutics. And we have now read out three phase three studies with DT120, two in GAD and one in MDD. And on the back of those three positive phase three readouts, we will be submitting an NDA to FDA in the first half of next year, and we intend to find a path to submit for both GAD and MDD. Open the document at this passage
Nov 9
Earnings call
DT120 heads toward 2027 NDA after three positive studies

Definium Therapeutics reported three positive phase 3 studies for DT120 in GAD and MDD, plans an NDA filing in the first half of 2027, and expects approximately $1.05 billion in cash and investments to fund operations into 2030.

4 source passages
Definium Therapeutics' third quarter 2026 financial results and recent Business Highlights conference call We have three positive phase 3 studies for DT120 and GAD and MDD, breakthrough therapy designations in both indications, and we remain on track for NDA filing in the first half of 2027. As of September 30th, 2026, cash, cash equivalents, and investments were approximately $1.05 billion, compared with $411.6 million as of December 31st, 2025. Based on our current operating plan and anticipated milestones, we expect these resources to fund planned operations into 2030. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
DT120 Phase 3 trials meet endpoints; cash runway into 2030

Definium Therapeutics’ DT120 Phase 3 trials met primary and key secondary endpoints in generalized anxiety disorder and major depressive disorder; approximately $1.0 billion in cash and investments at September 30, 2026 is expected to fund operations into 2030.

Net loss $50.96M Diluted EPS -$0.46
Read from the MD&A section
7 source passages
Our Phase 3 clinical program for DT120 ODT for GAD consists of two clinical trials: the Voyage study (DT120-300) and the Panorama study (DT120-301). On August 12, 2026, we announced that the Voyage study met its primary endpoint and all key secondary efficacy endpoints On September 14, 2026, we announced that the Panorama study met its primary endpoint and all key secondary efficacy endpoints Our Phase 3 clinical program for MDD consists of two clinical trials: the Emerge study (DT120-310) and the Ascend study (DT120-311). On June 22, 2026, we announced that the Emerge study met its primary and all key secondary efficacy endpoints Our cash, cash equivalents and investments and our working capital at September 30, 2026, were approximately $1.0 billion and $984.0 million, respectively. Based on our current operating plan and anticipated milestones, we believe that our cash, cash equivalents and investments as of September 30, 2026 will be sufficient to fund our operations into 2030. Open the document at this passage
Nov 9
Current report 8-K
Positive Phase 3 results move DT120 ODT toward filing

Definium Therapeutics reported positive Phase 3 DT120 ODT results, FDA Breakthrough Therapy Designation in major depressive disorder, and approximately $1.05 billion in cash as of September 30, 2026. It plans an NDA filing in the first half of 2027.

Financial results
5 source passages
Reported positive topline results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD) Received FDA Breakthrough Therapy Designation for DT120 ODT in major depressive disorder (MDD) Approximately $1.05 billion in cash, cash equivalents, and investments as of September 30, 2026 On track for DT120 ODT NDA filing in first half of 2027 NEW YORK, November 9, 2026 -- Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX) Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$337.48M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.01B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+59.9%
Year over year · more shares
Price change (1Y)
+155.2%
Trailing year
Short interest
7.0%
Latest settlement · 5.8 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 9, 2026
Q3 FY26

TL;DR. DT120 delivered consistent Phase 3 results across three studies, received an MDD Breakthrough Therapy designation, remains on track for a first-half 2027 NDA filing, and is supported by approximately $1.05 billion in liquidity; DT402 showed positive initial results and commercial preparation is advancing. R&D and G&A spending increased year over year, while DT402’s five-participant study had exploratory endpoints and was not powered to draw statistical conclusions.

Bullish
  • + DT120 produced consistent, clinically meaningful results across three Phase 3 studies in GAD and MDD.
  • + DT120 ODT received FDA Breakthrough Therapy designation in MDD.
  • + DT120 ODT remains on track for an NDA filing in the first half of 2027.
  • + Cash, cash equivalents and investments were approximately $1.05 billion and are expected to fund operations into 2030.
  • + DT402 showed positive initial results in its Phase 2a trial, with a multiple-dosing study planned for 2027.
  • + Commercial readiness activities and organizational capabilities are advancing toward commercialization.
Bearish
  • − Third-quarter 2026 R&D expenses increased to $46.1 million from $31.0 million in the prior-year period.
  • − Third-quarter 2026 G&A expenses increased to $26.1 million from $14.7 million in the prior-year period.
  • − DT402’s five-participant Phase 2a study had exploratory endpoints and was not powered to draw statistical conclusions.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −5%
below
Price vs 50-day avg −18%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 49%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −18%
trailing
6-month return +20%
trailing
YTD return +117%
this year
Relative strength +24%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $36 › 200d $31 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +60 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.02% of shares out · ▼ -4.3% MoM · 5.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
362 holders — near 3-yr high, broad support
Squeeze score 66
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 78%
annualized · 1-yr
Max drawdown −40%
past year
ATR 7.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−5% Neutral
Price vs 50-day avg
−18% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
49% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $36 › 200d $31 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +60 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.02% of shares out · ▼ -4.3% MoM · 5.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
362 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $11 Now $29 · 49% Range high $48
vs 200-day avg -5% vs 50-day avg -18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents and investments $1.1B As of June 30, 2026 —
DT120 GAD external research and development expenses 22.65M the three months ended June 30, 2026 filing —
DT120 MDD external research and development expenses 7.21M the three months ended June 30, 2026 filing —
DT120 other external research and development expenses 3.7M the three months ended June 30, 2026 filing —
DT402 program external research and development expenses 444K the three months ended June 30, 2026 filing —
Internal research and development costs 13.41M the three months ended June 30, 2026 filing —
MADRS: LS mean change at Week 12 (DT120 ODT 100 µg) -11 the three months ended June 30, 2026 filing —
MADRS: LS mean change at Week 12 (Placebo ODT) -3.6 the three months ended June 30, 2026 filing —
MADRS: LS mean change at Week 6 (DT120 ODT 100 µg) -13.3 the three months ended June 30, 2026 filing —
MADRS: LS mean change at Week 6 (Placebo ODT) -5.2 the three months ended June 30, 2026 filing —
MADRS: remission rate (≤12) at Week 6 (DT120 ODT 100 µg) 24% the three months ended June 30, 2026 filing —
MADRS: remission rate (≤12) at Week 6 (Placebo ODT) 3% the three months ended June 30, 2026 filing —
MADRS: response rate (≥50%) at Week 6 (DT120 ODT 100 µg) 35% the three months ended June 30, 2026 filing —
MADRS: response rate (≥50%) at Week 6 (Placebo ODT) 7% the three months ended June 30, 2026 filing —
Preclinical and other programs external research and development expenses 1.26M the three months ended June 30, 2026 filing —
Total DT120 program external research and development expenses 33.56M the three months ended June 30, 2026 filing —
Total external research and development expenses 35.26M the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DFTX
Definium Therapeutics, Inc.
this stock
$3.99B +117.5% — — 7.0%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
362
% held
86.1%
Net QoQ
+3.0M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
269
View
Short & Settlement
Short Interest Falling
Shares short
9.6M
Days to cover
5.8d
Change
-430.3K sh
View
Short Volume
Short vol %
68%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
504
Value
$19.2K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
51.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-183.8M
EPS diluted
$-2.06
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
23

Definium's CEO said the company expects to file an NDA for DT120 in the first half of next year after three positive pivotal readouts in generalized anxiety disorder and major depressive disorder. A second major depressive disorder pivotal readout is expected in 2027.

View
Proposed Sales
Value
$516.1K
Shares
14.1K
Filed
Sep 25, 2026
View
Exempt Offerings
Offering
$7.0M
Filed
May 5, 2025
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Definium Therapeutics Presents To…
Published
Nov 4, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
DFTX -15.5% -18.0% +20.4% -19.9% +117.5%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -11.6% -12.4% +23.9% -16.5% +110.4%
Key facts CIK 1813814 CUSIP 24477V105 13F (30d) 343 filings 335 filers Visit website Investor relations